Skip to main content

Table 4 Sensitivity analysis: NF-κB staining and ovarian tumor survival outcomes, the VUMC TROC

From: Expression of p52, a non-canonical NF-kappaB transcription factor, is associated with poor ovarian cancer prognosis

  Progression-free survival (PFS) Overall survival (OS)
HR (95% CI) a P-value HR (95% CI) a P-value
Nuclear or cytoplasmic p52
 Among all cases (N = 196) 1.94 (1.39–2.71) < 0.001 1.73 (1.24–2.43) 0.001
 Among chemotherapy naïve cases (N = 190) 2.00 (1.42–2.81) < 0.001 1.83 (1.30–2.58) < 0.001
 Among invasive cases (N = 177) 1.71 (1.21–2.42) 0.002 1.61 (1.14–2.29) 0.007
 Among serous cases (N = 143) 1.98 (1.34–2.92) < 0.001 1.90 (1.27–2.83) 0.002
 Among late stage cases (N = 137) 1.68 (1.14–2.47) 0.009 1.63 (1.10–2.41) 0.014
 Among invasive serous cases (N = 131) 1.89 (1.27–2.83) 0.002 1.91 (1.26–2.89) 0.003
 Among late stage serous cases (N = 119) 1.84 (1.21–2.81) 0.005 1.81 (1.17–2.80) 0.008
 Among high-grade serous cases (N = 118) 1.87 (1.21–2.87) 0.005 1.69 (1.09–2.62) 0.018
Nuclear or cytoplasmic p65
 Among all cases (N = 196) 1.31 (0.94–1.82) 0.113 1.30 (0.93–1.81) 0.127
 Among chemotherapy naïve cases (N = 190) 1.31 (0.93–1.83) 0.118 1.31 (0.93–1.85) 0.117
 Among invasive cases (N = 177) 1.33 (0.95–1.88) 0.100 1.33 (0.94–1.89) 0.108
 Among serous cases (N = 143) 1.04 (0.71–1.52) 0.860 1.20 (0.82–1.78) 0.352
 Among late stage cases (N = 137) 1.34 (0.93–1.93) 0.119 1.23 (0.85–1.77) 0.265
 Among invasive serous cases (N = 131) 1.15 (0.78–1.69) 0.482 1.30 (0.88–1.94) 0.193
 Among late stage serous cases (N = 119) 1.33 (0.89–1.99) 0.160 1.29 (0.86–1.93) 0.214
 Among high-grade serous cases (N = 118) 0.96 (0.63–1.47) 0.841 1.09 (0.71–1.69) 0.168
  1. a Adjusted for age at diagnosis (continuous)
\